ClinicalTrials.gg
RecruitingNCT07284758MOMENTUMUpdated Oct 30, 2026

A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma

A Phase 2 interventional study of Cemsidomide and Dexamethasone in Multiple Myeloma and Relapsed/Refractory Multiple Myeloma, sponsored by C4 Therapeutics, Inc.. Recruiting at 60 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-30.

Sponsored by C4 Therapeutics, Inc. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Feb 2026; still recruiting 8 months later.
Updated Oct 30, 2026First sites in 4 new countriesStudy contact changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
100
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 2,168 studies in Multiple Myeloma with a site in United States — 275 open to participants now, 503 under way, 66 of them phase 3. Multiple Myeloma · United States.

Planned enrollment
409th of 1,901
100 · median 36
Started
2026
with 75 others
Phase 2
751 of 2,168
76 open now
Primary completion
2030-03
later than 428 of 499 live
Registered
2,117th of 2,168
by date

Among the 2,168 studies in Multiple Myeloma with a site in United States, this one is the 409th largest by planned enrollment of the 1,901 interventional ones that give a count, is one of 76 that started in 2026, is one of 751 in phase 2, reaches primary completion later than 428 of the 499 other live ones, and was the 2,117th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

275 of the 2,168 studies in Multiple Myeloma with a site in United States are open now. Recruiting first, the newest first:

270 more — sign in →

All 275 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,168 studies in Multiple Myeloma with a site in United States, or all of them as a file.
02

Study summary

This is a Phase 2, open-label, single-arm, multicenter study to assess the antimyeloma activity and further characterize the safety, tolerability, PK, and PD of cemsidomide in combination with dexamethasone in participants with relapsed/refractory multiple myeloma (r/r MM).

03

Conditions studied

  • Multiple Myeloma
  • Relapsed/Refractory Multiple Myeloma

Browse trials for

Keywords

  • cemsidomide
  • dexamethasone
  • Multiple Myeloma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Be willing and able to provide signed for the study.
  2. Age ≥ 18 years at the time of signed consent.
  3. Subjects must have a documented diagnosis of MM and at enrollment.
  4. Received at least 3 prior anti-myeloma regimens (for a minimum of 2 or more consecutive cycles) that must have included an immunomodulatory drug (i.e., IKZF 1/3 degrader), a proteasome inhibitor, an anti-CD38 antibody, and a T-cell engager (TCE) or chimeric antigen receptor T-cell (CAR-T) therapy, unless not available per local standard of care.
  5. Subjects need to have adequate organ function.
  6. Toxicities from prior anticancer therapies must have resolved to baseline severity or ≤ Grade 1.
  7. Female subjects may not be pregnant or intend to become pregnant, may not breastfeed or intend to breastfeed, or donate ova during their participation in this study until 30 days after the last dose of study treatment.
  8. Male subjects must agree to use a condom when having intercourse with a person of during the Treatment Period and for at least 30 days after the last dose of study treatment.
  9. Male subjects must refrain from donating sperm during the Treatment Period and for 30 days after discontinuation.
  10. Subjects must refrain from donating blood during study treatment and for 30 days after discontinuation.

Exclusion criteria

Exclusion Criteria:

  1. Presence of myeloma in the central nervous system (CNS).
  2. Subjects with any of the following:

    • Systemic light chain amyloidosis
    • Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal gammopathy, and Skin changes (POEMS) Syndrome
    • Myelodysplastic syndrome (MDS).
  3. Previously treated with cemsidomide.
  4. impaired cardiac function or cardiac disease.
  5. Thromboembolic event within 3 months prior to enrollment.
  6. Known other than study indication that has progressed or required treatment within the past 3 years.
  7. Uncontrolled active bacterial, fungal, or viral infection.
  8. Inability or difficulty swallowing tablets.

NOTE: Other inclusion/exclusion criteria may apply, per protocol.

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Cemsidomide + Dexamethasone:

    Participants receive cemsidomide plus dexamethasone during a 28-day treatment cycle, and will continue to receive treatment until the participant meets one of the discontinuation criteria.

    Drug: Cemsidomide · Drug: Dexamethasone

Interventions

  • dosed orally (PO) once a day (QD) 14 days on/14 days off for each 28-day cycle

  • dosed PO once a week (QW) on Days 1, 8, 15, and 22 for each 28-day cycle

06

What researchers measure

Primary outcomes

  1. Overall response rate (ORR) per International Myeloma Working Group (IMWG) Response Criteria by an Independent Review Committee (IRC)

    Time frame: up to approximately 43 months

Secondary outcomes

  1. Duration of response (DoR; IRC assessed)

    Time frame: up to approximately 43 months

  2. Complete response (CR) rate (IRC assessed)

    Time frame: up to approximately 43 months

  3. Time to response (IRC assessed)

    Time frame: up to approximately 43 months

  4. Progression free survival (PFS; IRC assessed)

    Time frame: up to approximately 43 months

  5. Overall survival (OS)

    Time frame: up to approximately 43 months

  6. Adverse events (AEs); serious AEs (SAEs); AEs leading to treatment interruption, reduction, or discontinuation; and deaths

    Time frame: within 30 to 35 days of the last dose of study treatment

  7. Plasma concentrations of cemsidomide

    Time frame: up to approximately 4 months

07

Study locations

33 of 60 sites recruiting
  • Clearview Cancer Institute
    Huntsville, Alabama 35805, United States
    Recruiting
    • Lakshmikanth Katragadda, MD · Contact
  • Mayo Clinic - Arizona
    Phoenix, Arizona 85054, United States
    Recruiting
    • Saurabh Chhabra, MD · Contact
  • HonorHealth
    Scottsdale, Arizona 85258, United States
    Recruiting
    • Rizwan Khawaja, MD · Contact
  • City of Hope
    Duarte, California 91010, United States
    Recruiting
    • Michael Rosenzweig, MD · Contact
  • Berenson Cancer Center
    West Hollywood, California 90069, United States
    Recruiting
    • James Berenson, MD · Contact
  • Mayo Clinic - Florida
    Jacksonville, Florida 32224, United States
    Recruiting
    • Sikander Ailawadhi, MD · Contact
  • Winship Cancer Institute, Emory University
    Atlanta, Georgia 30322, United States
    Recruiting
    • Nisha Joseph, MD · Contact
  • Indiana University Health
    Indianapolis, Indiana 46202, United States
    Recruiting
    • Attaya Suvannasankha, MD · Contact
  • University of Iowa
    Iowa City, Iowa 52242, United States
    Recruiting
    • Christopher Strouse, MD · Contact
  • Beth Israel Deaconess Medical Center
    Boston, Massachusetts 02114, United States
    Not yet recruiting
    • Jessica Ligel, MD · Contact
  • Dana Farber Cancer Institute
    Boston, Massachusetts 02114, United States
    Not yet recruiting
    • Paul Richardson, MD · Contact
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
    Recruiting
    • Andrew Yee, MD · Contact
  • University of Michigan
    Ann Arbor, Michigan 48109, United States
    Recruiting
    • Matthew Piakno, MD · Contact
  • Karmanos Cancer Institute
    Detroit, Michigan 48201, United States
    Recruiting
    • Craig Cole, MD · Contact
  • START Midwest
    Grand Rapids, Michigan 49546, United States
    Recruiting
    • Andrew Sochacki, MD · Contact
  • Mayo Clinic - Minnesota
    Rochester, Minnesota 55905, United States
    Recruiting
    • Wilson Gonsalves, MD · Contact
  • Washington University/Siteman Cancer Center
    St Louis, Missouri 63108, United States
    Recruiting
    • Mark Schroeder, MD · Contact
  • University of Nebraska Medical Center
    Omaha, Nebraska 68198, United States
    Recruiting
    • Sarah Holstein, MD · Contact
  • The Tisch Cancer Institute/Mount Sinai
    New York, New York 10029, United States
    Recruiting
    • Shambavi Richard, MD · Contact
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
    Recruiting
    • Hamza Hashmi, MD · Contact
  • UNC Hospitals Adult Oncology Clinics
    Chapel Hill, North Carolina 27514, United States
    Recruiting
    • Sascha Tuchman, MD · Contact
  • Tennessee Oncology
    Nashville, Tennessee 37203, United States
    Recruiting
    • Jesus Berdeja, MD · Contact
  • START San Antonio
    San Antonio, Texas 78229, United States
    Recruiting
    • Kyriakos Papadopoulos, MD · Contact
  • University of Wisconsin - Carbone Cancer Center
    Madison, Wisconsin 53792, United States
    Recruiting
    • Natalie Callander, MD · Contact
  • MCW-Clinical Cancer Center at Froedtert Hospital Campus
    Milwaukee, Wisconsin 53226, United States
    Recruiting
    • Binod Dhakal, MD · Contact
  • Centre Hospitalier de la Côte Basque
    Bayonne, France
    Recruiting
    • Julie Gay, MD · Contact
  • Hospices Civils de Lyon (HCL) - Centre Hospitalier Lyon-Sud
    Lyon, France
    Not yet recruiting
    • Lionel Karlin, MD · Contact
  • Institut Paoli-Calmettes (IPC)
    Marseille, France
    Not yet recruiting
    • Jean-Marc Schiano de Colella, MD · Contact
  • Centre Henri-Becquerel
    Rouen, France
    Not yet recruiting
    • Pascal Lenain, MD · Contact
  • Centre Hospitalier Universitaire (CHU) de Toulouse-Institut Universitaire du Cancer de Toulouse-Oncopole (IUCT-Oncopole)
    Toulouse, France
    Not yet recruiting
    • Aurore Perrot, MD · Contact
  • Centre Hospitalier Regional et Universitaire de Tours (CHRU Tours) Hospital Bretonneau
    Tours, France
    Not yet recruiting
    • Thomas Chalopin, MD · Contact
  • Institut Gustave Roussy
    Villejuif, France
    Not yet recruiting
    • Vincent Ribrag, MD · Contact
  • Servizio Sanitario Regionale Emilia-Romagna-Istituto Scientifico Romagnolo per lo Studio dei Tumori "Dino Amadori" Srl
    Meldola, Italy
    Not yet recruiting
    • Claudio Cerchione, MD · Contact
  • Azienda Ospedaliera Universitaria (AOU) "Federico II"
    Naples, Italy
    Not yet recruiting
    • Fabrizio Pane, MD · Contact
  • Universita degli Studi di Pavia-Fondazione IRCCS Policlinico San Matteo
    Pavia, Italy
    Not yet recruiting
    • Silvia Mangiacavalli, MD · Contact
  • Servizio Sanitario Regionale Emilia-Romagna - Ematologia Ospedale Infermi di Rimini
    Rimini, Italy
    Not yet recruiting
    • Francesco Rotondo, MD · Contact
  • Azienda Sanitaria Locale (ASL) Roma 1 - Ospedale Santo Spirito
    Roma, Italy
    Not yet recruiting
    • Tommaso Caravita di Toritto, MD · Contact
  • Ospedale Casa Sollievo della Sofferenza
    San Giovanni Rotondo, Italy
    Recruiting
    • Angelo Michele Carella, MD · Contact
  • IN-VIVO Sp.z.o.o
    Bydgoszcz, Poland
    Not yet recruiting
    • Jaroslaw Czyz, MD · Contact
  • Uniwersyteckie Centrum Kliniczne w Gdańsku
    Gdansk, Poland
    Not yet recruiting
    • Agata Tyczynska, MD · Contact
  • Pratia Hematologia Sp. Z o. o
    Katowice, Poland
    Recruiting
    • Sebastian Grosicki, MD · Contact
  • Uniwersytecki Szpital Kliniczny Im. Jana Mikulicza-Radeckiego We Wroclawiu
    Wroclaw, Poland
    Not yet recruiting
    • Tomasz Wrobel, MD · Contact
  • Hospital Clínic de Barcelona
    Barcelona, Spain
    Not yet recruiting
    • Laura Rosiñol Dachs, MD · Contact
  • Institut Catala d'Oncologia (ICO) Badalona - Hospital Germans Trias i Pujol
    Barcelona, Spain
    Not yet recruiting
    • Gladys Ibarra Fernández, MD · Contact
  • Institut Català d'Oncologia (ICO) L'hospitalet
    Barcelona, Spain
    Not yet recruiting
    • Itziar Carro Arostegui, MD · Contact
  • Hospital Clínico Universitario Virgen de la Arrixaca
    El Palmar, Spain
    Not yet recruiting
    • Valentin Cabañas Perianes, MD · Contact
  • Hospital Universitario de Cabueñes
    Gijón, Spain
    Not yet recruiting
    • Maria Esther Gonzalez Garcia, MD · Contact
  • Complejo Asistencial Universitario de León
    León, Spain
    Not yet recruiting
    • Fernando Escalante-Barrigón, MD · Contact
  • Hospital Universitario HM Sanchinarro
    Madrid, Spain
    Not yet recruiting
    • Luis Felipe Casado Montero, MD · Contact
  • Clinica Universidad de Navarra
    Pamplona, Spain
    Not yet recruiting
    • Paula Rodríguez Otero, MD · Contact
  • Complejo Asistencial Universitario De Salamanca (CAUSA)
    Salamanca, Spain
    Not yet recruiting
    • Maria Victoria Mateos Manteca, MD · Contact
  • The Royal Marsden NHS Foundation Trust
    Sutton, Surrey, United Kingdom
    Recruiting
    • Martin Kaiser, MD · Contact
  • Imperial College Healthcare NHS Foundation Trust - Hammersmith Hospital
    London, United Kingdom, United Kingdom
    Recruiting
    • Aristeidis Chaidos, MD · Contact
  • NHS Lothian - Western General Hospital- Edinburgh Cancer Centre
    Edinburgh, United Kingdom
    Recruiting
    • Victoria Campbell, MD · Contact
  • The Leeds Teaching Hospitals NHS Trust - St James's University Hospital
    Leeds, United Kingdom
    Recruiting
    • Christopher Parrish, MD · Contact
  • The King's College Hospital NHS Foundation Trust
    London, United Kingdom
    Recruiting
    • Kirsty Cuthill, MD · Contact
  • The Christie NHS Foundation Trust
    Manchester, United Kingdom
    Recruiting
    • Emma Searle, MD · Contact
  • Newcastle University Hospitals NHS Foundation Trust
    Newcastle upon Tyne, United Kingdom
    Recruiting
    • Andrew Charlton, MD · Contact
  • GenesisCare, Beaumont House
    Oxford, United Kingdom
    Not yet recruiting
    • Karthik Ramasamy, MD · Contact
  • GenesisCare, Windsor
    Windsor, United Kingdom
    Not yet recruiting
    • Jaimal Kothari, MD · Contact
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Mar 2030, 49 months after the start.

Of 93 industry-sponsored phase 2 interventional studies under Multiple Myeloma, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 77. This study's planned 49 months is above that.

Counting every sponsor, half of 506 studies reached it within 57 months; a quarter within 35 and three quarters within 95.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 9, 2025
First posted
Dec 16, 2025
StartActual
Feb 18, 2026
Primary completionEst.
Mar 2030
CompletionEst.
Mar 2030
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
39 sites added — first sites in France, Italy, Poland and Spain
Show 39 added (9 Spain, 8 United Kingdom, 7 France, 6 Italy, 5 United States, 4 Poland)
  • City of Hope · Duarte, United States
  • Beth Israel Deaconess Medical Center · Boston, United States
  • Dana Farber Cancer Institute · Boston, United States
  • Massachusetts General Hospital · Boston, United States
  • University of Michigan · Ann Arbor, United States
  • Centre Hospitalier de la Côte Basque · Bayonne, France
  • Hospices Civils de Lyon (HCL) - Centre Hospitalier Lyon-Sud · Lyon, France
  • Institut Paoli-Calmettes (IPC) · Marseille, France
  • Centre Henri-Becquerel · Rouen, France
  • Centre Hospitalier Universitaire (CHU) de Toulouse-Institut Universitaire du Cancer de Toulouse-Oncopole (IUCT-Oncopole) · Toulouse, France
  • Centre Hospitalier Regional et Universitaire de Tours (CHRU Tours) Hospital Bretonneau · Tours, France
  • Institut Gustave Roussy · Villejuif, France
  • Servizio Sanitario Regionale Emilia-Romagna-Istituto Scientifico Romagnolo per lo Studio dei Tumori "Dino Amadori" Srl · Meldola, Italy
  • Azienda Ospedaliera Universitaria (AOU) "Federico II" · Naples, Italy
  • Universita degli Studi di Pavia-Fondazione IRCCS Policlinico San Matteo · Pavia, Italy
  • Servizio Sanitario Regionale Emilia-Romagna - Ematologia Ospedale Infermi di Rimini · Rimini, Italy
  • Azienda Sanitaria Locale (ASL) Roma 1 - Ospedale Santo Spirito · Roma, Italy
  • Ospedale Casa Sollievo della Sofferenza · San Giovanni Rotondo, Italy
  • IN-VIVO Sp.z.o.o · Bydgoszcz, Poland
  • Uniwersyteckie Centrum Kliniczne w Gdańsku · Gdansk, Poland
  • Pratia Hematologia Sp. Z o. o · Katowice, Poland
  • Uniwersytecki Szpital Kliniczny Im. Jana Mikulicza-Radeckiego We Wroclawiu · Wroclaw, Poland
  • Hospital Clínic de Barcelona · Barcelona, Spain
  • Institut Catala d'Oncologia (ICO) Badalona - Hospital Germans Trias i Pujol · Barcelona, Spain
  • Institut Català d'Oncologia (ICO) L'hospitalet · Barcelona, Spain
  • Hospital Clínico Universitario Virgen de la Arrixaca · El Palmar, Spain
  • Hospital Universitario de Cabueñes · Gijón, Spain
  • Complejo Asistencial Universitario de León · León, Spain
  • Hospital Universitario HM Sanchinarro · Madrid, Spain
  • Clinica Universidad de Navarra · Pamplona, Spain
  • …and 9 more on the registry record
Oct 30, 2026
Contact
Study contact changed: added s•••@sparkcures.com · •••2873. See the current contact
Oct 30, 2026
Show all 1 update
  1. Oct 30, 2026
    39 sites added — first sites in France, Italy, Poland and Spain
    Show 39 added (9 Spain, 8 United Kingdom, 7 France, 6 Italy, 5 United States, 4 Poland)
    • City of Hope · Duarte, United States
    • Beth Israel Deaconess Medical Center · Boston, United States
    • Dana Farber Cancer Institute · Boston, United States
    • Massachusetts General Hospital · Boston, United States
    • University of Michigan · Ann Arbor, United States
    • Centre Hospitalier de la Côte Basque · Bayonne, France
    • Hospices Civils de Lyon (HCL) - Centre Hospitalier Lyon-Sud · Lyon, France
    • Institut Paoli-Calmettes (IPC) · Marseille, France
    • Centre Henri-Becquerel · Rouen, France
    • Centre Hospitalier Universitaire (CHU) de Toulouse-Institut Universitaire du Cancer de Toulouse-Oncopole (IUCT-Oncopole) · Toulouse, France
    • Centre Hospitalier Regional et Universitaire de Tours (CHRU Tours) Hospital Bretonneau · Tours, France
    • Institut Gustave Roussy · Villejuif, France
    • Servizio Sanitario Regionale Emilia-Romagna-Istituto Scientifico Romagnolo per lo Studio dei Tumori "Dino Amadori" Srl · Meldola, Italy
    • Azienda Ospedaliera Universitaria (AOU) "Federico II" · Naples, Italy
    • Universita degli Studi di Pavia-Fondazione IRCCS Policlinico San Matteo · Pavia, Italy
    • Servizio Sanitario Regionale Emilia-Romagna - Ematologia Ospedale Infermi di Rimini · Rimini, Italy
    • Azienda Sanitaria Locale (ASL) Roma 1 - Ospedale Santo Spirito · Roma, Italy
    • Ospedale Casa Sollievo della Sofferenza · San Giovanni Rotondo, Italy
    • IN-VIVO Sp.z.o.o · Bydgoszcz, Poland
    • Uniwersyteckie Centrum Kliniczne w Gdańsku · Gdansk, Poland
    • Pratia Hematologia Sp. Z o. o · Katowice, Poland
    • Uniwersytecki Szpital Kliniczny Im. Jana Mikulicza-Radeckiego We Wroclawiu · Wroclaw, Poland
    • Hospital Clínic de Barcelona · Barcelona, Spain
    • Institut Catala d'Oncologia (ICO) Badalona - Hospital Germans Trias i Pujol · Barcelona, Spain
    • Institut Català d'Oncologia (ICO) L'hospitalet · Barcelona, Spain
    • Hospital Clínico Universitario Virgen de la Arrixaca · El Palmar, Spain
    • Hospital Universitario de Cabueñes · Gijón, Spain
    • Complejo Asistencial Universitario de León · León, Spain
    • Hospital Universitario HM Sanchinarro · Madrid, Spain
    • Clinica Universidad de Navarra · Pamplona, Spain
    • …and 9 more on the registry record
    Contact Study contact changed: added s•••@sparkcures.com · •••2873. See the current contact
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07284758
Lead sponsor
C4 Therapeutics, Inc.
Responsible party
Sponsor
First posted
Dec 16, 2025
Start date
Feb 18, 2026
Primary completion
Mar 2030 (estimated)
Completion
Mar 2030 (estimated)
Last update
Oct 30, 2026

Study contacts

Study Medical Officer
Contact
clinicaltrials@c4therapeutics.com
(617) 231-0700
Patient Navigator
Contact
support+c4@sparkcures.com
(888) 676-2873
Binod Dhakal, M.D.
principal investigator · Medical College of Wisconsin
Martin Kaiser, M.D.
principal investigator · The Royal Marsden
Aurore Perrot, M.D.
principal investigator · Universite de Toulouse

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cemsidomide

Start the discussion